Advertisement

Case Study: Drug Eluting Stent

  • Filippo Rossi
  • Giuseppe Perale
  • Maurizio Masi
Chapter
Part of the SpringerBriefs in Applied Sciences and Technology book series (BRIEFSAPPLSCIENCES)

Abstract

In drug eluting stent technologies, an increased demand for better control, higher reliability and enhanced performances of drug delivery systems emerged in the last years and thus offered the opportunity to introduce model-based approaches aimed to overcome the remarkable limits of trial–and-error methods. In this context a chemical engineering approach was studied, being based on the detailed conservation equations and taking into account the main physical–chemical mechanisms involved in polymeric coating degradation, drug release and restenosis inhibition. It allowed highlighting the interdependence between factors affecting each of these phenomena and, in particular, the influences of stent design parameters on drug antirestenotic efficacy. The hierarchical structure of this model also allows easily modifying the set of equations describing restenosis evolution in order to enhance model reliability and taking advantage of the deep understanding of physiological mechanisms governing the different stages of smooth muscle cell growth and proliferation. In addition, thanks to its simplicity and to the very low system requirements and CPU time, our model allows obtaining immediate views of system behavior.

Keywords

Drug eluting stent Mathematical modeling Restenosis 

References

  1. Bagust, A., Grayson, A. D., Palmer, N. D., Perry, R. A., & Walley, T. (2006). Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study. Heart, 92, 68–74.CrossRefGoogle Scholar
  2. Dawkins, K. D., Grube, E., Guagliumi, G., Banning, A. P., Zmudka, K., Colombo, A., et al. (2005). Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial—Support for the use of drug-eluting Stents in contemporary clinical practice. Circulation, 112, 3306–3313.CrossRefGoogle Scholar
  3. Finkelstein, A., McClean, D., Kar, S., Takizawa, K., Varghese, K., Baek, N., et al. (2003). Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation, 107, 777–784.CrossRefGoogle Scholar
  4. Franks, S. J., Byrne, H. M., King, J. R., Underwood, J. C. E., & Lewis, C. E. (2003a). Modelling the early growth of ductal carcinoma in situ of the breast. Journal of Mathematical Biology, 47, 424–452.zbMATHMathSciNetCrossRefGoogle Scholar
  5. Franks, S. J., Byrne, H. M., King, J. R., Underwood, J. C. E., & Lewis, C. E. (2003b). Modelling the early growth of ductal carcinoma in situ of the breast. Journal of Mathematical Biology, 47, 424–452.zbMATHMathSciNetCrossRefGoogle Scholar
  6. Kastrati, A., Dibra, A., Eberle, S., Mehilli, J., de Lezo, J. S., Goy, J. J., et al. (2005). Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease—Meta-analysis of randomized trials. JAMA, 294, 819–825.CrossRefGoogle Scholar
  7. Lemos, P. A., Serruys, P. W., & Sousa J. E. (2003). Drug-eluting stents. Cost vs clinical benefit. Circulation, 107, 3003–3007.Google Scholar
  8. Levin, A. D., Vukmirovic, N., Hwang, C. W., & Edelman, E. R. (2004). Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc. Natl Acad. Sci. U S A, 101, 9463–9467.CrossRefGoogle Scholar
  9. McFadden, E. P., Stabile, E., Regar, E., Cheneau, E., Ong, A. T. L., Kinnaird, T., et al. (2004). Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet, 364, 1519–1521.CrossRefGoogle Scholar
  10. Ong, A. T. L., Serruys, P. W., Aoki, J., Hoye, A., van Mieghem, C. A. G., Rodriguez-Granillo, G. A., et al. (2005). The unrestricted use of paclitaxel-versus sirolimus-eluting stents for coronary artery disease in an unselected population—One-year results of the Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) registry. Journal of the American College of Cardiology, 45, 1135–1141.CrossRefGoogle Scholar
  11. Scheller, B., Speck, U., Schmitt, A., Bohm, M., & Nickenig, G. (2003). Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. Journal of the American College of Cardiology, 42, 1415–1420.CrossRefGoogle Scholar
  12. Schwartz, R. S., Chronos, N. A., & Virmani, R. (2004). Preclinical restenosis models and drug-eluting stents - Still important, still much to learn. Journal of the American College of Cardiology, 44, 1373–1385.Google Scholar
  13. Serruys PW and Gershlick A (2005) In Handbook of Drug-Eluting Stents. Vol. pp. CRC Press, New York,Google Scholar
  14. Sousa, J. E., Costa, M. A., Abizaid, A., Abizaid, A. S., Feres, F., Pinto, I. M. F., et al. (2001). Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries—A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation, 103, 192–195.CrossRefGoogle Scholar
  15. Sousa, J. E., Serruys, P. W., & Costa, M. A. (2003). New frontiers in cardiology—Drug-eluting stents: Part II. Circulation, 107, 2383–2389.CrossRefGoogle Scholar
  16. Steigerwald, K., Merl, S., Kastrati, A., Wieczorek, A., Vorpahl, M., Mannhold, R., et al. (2009). The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts. Biomaterials, 30, 632–637.CrossRefGoogle Scholar
  17. Stone, G. W., Ellis, S. G., Cox, D. A., Hermiller, J., O’Shaughnessy, C., Mann, J. T., et al. (2004a). One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS Stent the TAXUS-IV trial. Circulation, 109, 1942–1947.CrossRefGoogle Scholar
  18. Stone, G. W., Ellis, S. G., Cox, D. A., Hermiller, J., O’Shaughnessy, C., Mann, J. T., et al. (2004b). A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. New England Journal of Medicine, 350, 221–231.CrossRefGoogle Scholar
  19. Tanimoto, S., Daemen, J., Tsuchida, K., Garcia-Garcia, H. M., de Jaegere, P., van Dornburg, R. T., et al. (2007). Two-year clinical outcome after coronary stenting of small vessels using 2.25-mm sirolimus- and paclitaxel-eluting stents: Insight into the RESEARCH and T-SEARCH registries. Catheterization and Cardiovascular Interventions, 69, 94–103.CrossRefGoogle Scholar
  20. Togni, M., Eber, S., Widmer, J., Billinger, M., Wenaweser, P., Cook, S., et al. (2007). Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents—A subgroup analysis of the SIRTAX trial. Journal of the American College of Cardiology, 50, 1123–1131.CrossRefGoogle Scholar
  21. Venkatraman, S., & Boey, F. (2007). Release profiles in drug-eluting stents: Issues and uncertainties. J. Control. Release, 120, 149–160.CrossRefGoogle Scholar
  22. Virmani, R., Guagliumi, G., Farb, A., Musumeci, G., Grieco, N., Motta, T., et al. (2004). Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent should we be cautious? Circulation, 109, 701–705.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2016

Authors and Affiliations

  1. 1.Department of Chemistry, Materials and Chemical EngineeringPolitecnico di MilanoMilanoItaly
  2. 2.Innovative TechnologiesSUPSIMannoSwitzerland
  3. 3.Department of Chemistry, Materials and Chemical EngineeringPolitecnico di MilanoMilanoItaly

Personalised recommendations